2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1621 Clinical, biological, and race/ethnicity-associated determinants of treatment response and survival in IDH1-mutated acute myeloid leukemia (AML): A multicenter multivariate analysis from the MARROW consortium

Jennifer Marvin-Peek, MD, Onyee Chan, MD2, Alexander Joseph Ambinder, MD, MPH3, Yazan F. Madanat, MD4, Kuo-Kai Chin, M.D.5, Ann Mercurio, MD6, Vanessa Kennedy7, Yamuna Kondapally, MD8, Tapan Kadia I, MD9, Naval Daver, MD10, Alice Scott Mims, MD11, Electra D Paskett, PhD12, Ilias Oulidi Jerrar Oulidi, MD13, Praneeth Baratam, MBBS14, Deedra Nicolet, MS15, Krzysztof Mrózek, MD, PhD16, Michael Walker17, Utsav Joshi, MD18, Najla Al Ali, MS19, Haley Roberts20, Thomas Kehoe21, Akriti G Jain, MD, FACP22, Charles Foucar, MD23, Abhay Singh, MD, MPH24, Sean Ormond25, Madelyn Burkart, MD26, David Swoboda, MD27, Elaine Mardis, PhD28, B. Douglas Smith, MD29, Courtney DiNardo, MD, MSCE30, Daniel Pollyea, MD31, Ann-Kathrin Eisfeld, MD32
1 The University of Texas MD Anderson Cancer Center, Houston, United States
2 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
3 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
4 Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai Morningside/West, New York, New York, United States
7 Stanford Cancer Institute, Stanford University, Stanford, California, United States
8 Stanford Cancer Institute, Stanford University, Stanford, California, United States
9 The University of Texas MD Anderson Cancer Center, Houston, United States
10 The University of Texas MD Anderson Cancer Center, Houston, United States
11 Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
12 College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
13 MUSC Health Florence Medical Center, Florence, South Carolina, United States
14 Medical University of South Carolina, Charleston, South Carolina, United States
15 Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
16 Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
17 Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
18 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
19 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
20 Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
21 University of South Florida Morsani College of Medicine, Tampa, Florida, United States
22 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
23 University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
24 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
25 Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
26 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
27 Tampa General Hospital Cancer Institute, Tampa, Florida, United States
28 Nationwide Children’s Hospital, Columbus, Ohio, United States
29 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States
30 The University of Texas MD Anderson Cancer Center, Houston, United States
31 University of Colorado, Aurora, Colorado, United States
32 Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Background: The development of targeted therapies has expanded frontline treatment options for patients (pts) with IDH1-mutated (IDH1mut) AML including intensive chemotherapy (IC) ± ivosidenib (IVO), hypomethylating agents (HMA) ± venetoclax (VEN), and HMA+IVO. However, evidence supporting these approaches is largely derived from cohorts of White non-Hispanic (NH) pts with limited representation of other racial and ethnic groups. We therefore evaluated the associations between self-reported race/ethnicity (R/E), treatment response, and survival among pts with IDH1mut AML receiving contemporary frontline therapies.

Methods: We identified 825 adults with newly diagnosed IDH1mut AML from a collaborative effort of the 11 institutions of the Myeloid Malignancy Association on Rapid Research Outcomes Working Group (MARROW; n=315), MDACC (n=105), and data obtained from the Flatiron Health database (n=405; AACR/Flatiron Health Real World Impact Award) between 2013 and 2025. Pts receiving triplet therapies were excluded. Primary outcomes included composite complete remission (CRc) rate and overall survival (OS). Variables considered in univariate analyses (UVA) were R/E, age, sex, platelet count, RAS pathway mutations, normal karyotype, DNMT3Amut, NPM1mut, AML-MR, treatment [categorized by intensity (intensive vs non-intensive) and IVO exposure (yes vs no)], and receipt of SCT. Multivariate analyses (MVAs) were constructed using backward selection of variables with p<0.05 on UVA.

Results: Among the 825 pts, 202 (24%) self-identified as non-NH-White, including 94 (11%) NH-Black, 72 (9%) Hispanic, and 36 (4%) Asian. Individuals who self-identified as R/R groups other than NH-White were younger at diagnosis than NH-White individuals (median age 65 vs 70 years, p<0.001). Baseline cytogenetics and molecular profiles were similar across R/E groups, with DNMT3Amut, NPM1mut, ASXL1mut and RUNX1mut being the most common co-occurring mutations. Frontline therapy for all R/E groups consisted of IC (n=339, 41%), IC+IVO (n=26, 3%), HMA+VEN (n=227, 28%), HMA+IVO (n=83, 10%), and HMA alone (n=105, 13%). Treatment differed significantly by R/E group (p<0.001), with non-White pts more likely to receive IC (51% vs 38%) and less likely to receive HMA+VEN (21% vs 30%) or HMA alone (8% vs 14%) than NH-White pts. There was no significant difference in frequency of allogeneic stem cell transplant (SCT).

Overall, in 815 pts evaluable for response, the CRc rate was 66% for NH-White and 68% for non-NH-White pts (p=0.54). CRc rates were lowest in Black and NH-White pts (60% and 66%, respectively), compared to 73% and 81% in Hispanic and Asian pts (p=0.05). In univariate analyses, race was significantly associated with odds of achieving CRc, along with age, sex, platelet count, normal karyotype, use of intensive chemotherapy, DNMT3Amut and NPM1mut. Receipt of IVO was not associated with increased odds of CRc. In MVA controlling for age, platelet count, use of IC, and karyotype, R/E remained independently associated with CRc, with Black pts having significantly lower odds of achieving a CRc (OR 0.39, 95% CI 0.21-0.72, p=0.01) compared to NH-White pts. Hispanic and Asian pts had similar odds of achieving CRc compared with White pts (OR, 1.02; 95% CI, 0.47-2.20 and OR, 1.92; 95% CI, 0.61-6.08, respectively).

With a median follow-up of 34 months, the 3-year overall survival (OS) was 54.6% and 46.2% for non-NH-White and NH-White pts, respectively. Variables significantly associated with OS on univariate analyses included race, age, platelet count, normal karyotype, NPM1mut, use of intensive chemotherapy, and SCT. In MVA controlling for age, platelet count, karyotype, receipt of SCT, treatment intensity, and use of IVO, R/E retained its independent prognostic significance with OS (overall p=0.01). Compared with NH-White pts, Asian pts had significantly improved survival (HR, 0.37, 95% CI 0.20-0.70), whereas Hispanic (HR, 0.78, 95% CI 0.53-1.16) and Black pts (HR, 1.03, 95% CI 0.75-1.42) had similar survival outcomes.

Conclusions: In the largest multi-institutional analysis of pts with IDH1mut AML, R/E remained independently associated with treatment response and survival despite comparable baseline cytogenetic and molecular characteristics. These findings highlight the importance of proportional R/E representation in clinical trials and real-world datasets to ensure equitable characterization of treatment outcomes across diverse populations.

Jennifer Marvin-Peek, MD: Servier - Consultancy (Includes expert testimony); Rigel - Consultancy (Includes expert testimony); Blueprint - Consultancy (Includes expert testimony)